Skip to main content
Darkfield

Ransomware victim disclosure

← All victims

Nang Kuang Pharmaceutical Co., Ltd.

Claimed by Incransom · listed 4 months ago

430 GB
Data size
$70M
Est. revenue
company size proxy
3m
Age
since listed · data leaked

Status timeline

  1. ListedFeb 15, 2026
  2. Data leakeddate unknown

At a glance

Group
Incransom
Status
Data leaked
Country
Taiwan
Sector
Healthcare
Listed on leak site
Feb 15, 2026
Data size
430 GB
Estimated revenue
$70M

About the victim

AI dossier — public-source company profile

Nang Kuang Pharmaceutical Co., Ltd. is a Taiwan-based pharmaceutical company operating under the domain nangkuang.com.tw with a reported annual revenue of approximately $70 million USD. The company is involved in the development and manufacturing of pharmaceutical products, including branded drugs such as Eroxon, Cinacalcet, Icatibant, Exparel, and bupivacaine. It maintains partnerships and client relationships with major global pharmaceutical firms including Pfizer, PeptiStar Inc., Shiratori Pharmaceutical, and Somerset Pharma LLC.

Industry
Pharmaceutical Manufacturing & Contract Research

Attack summary

Severity: critical — The exfiltration involves 430 GB of highly regulated pharmaceutical data including clinical trial reports across all phases, personal identification information, NDAs/CDAs, regulatory filings (DMF, GMP, CRF), and litigation documents tied to a major partner (Pfizer). This constitutes a large-scale breach of sensitive medical, legal, and personal data with significant regulatory and commercial implications.

The Incransom group claims to have exfiltrated approximately 430 GB of highly sensitive data from Nang Kuang Pharmaceutical, with full publication threatened within four weeks. The stolen data allegedly includes confidential clinical trial records, regulatory and legal documents, NDAs/CDAs, personal identification information, and proprietary pharmaceutical project data.

critical

Data the group says was taken

AI dossier — extracted from the leak post
  • Client and partner records (Rosetta, PeptiStar, Pfizer, etc.)
  • Confidential and secret classified data
  • Drug development project files (Eroxon, Cinacalcet, Icatibant, Exparel, bupivacaine)
  • Contractual agreements
  • Pfizer-related lawsuit documents
  • Clinical reports (inception to late phase)
  • Personal identification scans (ID scans)
  • Email data
  • Confidentiality and Non-Disclosure Agreements (CDA/NDA)
  • Clinical Review documents
  • Product Risk Assessments
  • Regulatory/Good Manufacturing Practice (GMP) records
  • Drug Master Files (DMF)
  • Case Report Forms (CRF)
  • RGD and RDO documentation

What the group claims

Nang Kuang Pharmaceutical Co. Ltd Revenue: 70M$ Nang Kuang Pharmaceutical Co. Ltd, nangkuang.com.tw , Total data in the leak: 430GB Leaked data: - Clients and Parners: Rosetta, PeptiStar Inc, Shiratori Pharmaceutical Co Ltd, Apexcela co. ltd, Somerset Pharma LLC., CureLeads FZ-LLC., Pfizer and other companies worldwide - Data Classification: confidential / Secret - Projects: Eroxon, Cinacalcet, Icatibant, Exparel, bupivacaine and many other medical drugs Data: Agreements, projects, lawsuits from Pfizer, clinical reports from inception to late phase, Personal info (ID scans), emails data, CDA and NDA, Clinical Review, Product Risk Assessment, RGD, RDO, DMF, GMP, CRF And a lot of other VERY IMPORTANT information! Full publication within four weeks!

Sources

Source

Indexed 4 months ago

This page surfaces a public ransomware disclosure indexed by Darkfield. Original posts come from the operator's own leak site; we cross-check against ransomware.live, RansomLook and RansomWatch where applicable. Share this URL freely.

Is this your supplier? Your competitor? You?

Pro plans monitor your domain, corporate emails, and crypto wallets across every new ransomware leak-site post, breach dump and Telegram callout — alerts within 5 minutes.

Disclosure context

About Incransom

Incransom is a ransomware group that emerged in August 2023, operating with primarily financial motivations as evidenced by their targeting of high-value sectors across multiple developed nations. The group's origin and specific affiliations remain undocumented by major threat intelligence organizations, though their operational patterns suggest they likely operate independently rather than as a ransomware-as-a-service model. With 734 documented victims, Incransom has demonstrated a preference for targeting organizations in the United States, Canada, United Kingdom, Germany, and Australia, with particular focus on healthcare, technology, business services, and manufacturing sectors, though their attack methodology and specific technical capabilities have not been extensively documented by established security researchers or government agencies. The group's notable campaigns and specific high-profile victims have not been publicly detailed by CISA, FBI, Mandiant, or other reputable threat intelligence sources, suggesting either operational security effectiveness or limited visibility into their most significant operations. Based on available intelligence, Incransom appears to remain active as of recent reporting periods, though comprehensive analysis of their current operational status requires additional documentation from established threat intelligence sources. The group has been linked to 829 public disclosures across our corpus. First observed on a leak site on August 9, 2023; most recent post June 11, 2026. The operation is currently active.

Also tracked as: inc ransom.

Timeline of this disclosure

  • February 15, 2026Nang Kuang Pharmaceutical Co., Ltd. listed by Incransomon the group's public leak site
Data size
430 GB

Other recent disclosures by Incransom

Incransom has been linked to 829 public victims on Darkfield. A sample of the most recent:

See the full Incransom dossier →

Sector and geography

This disclosure adds to ransomware activity in the Healthcare sector, which has 1,780 disclosures indexed across all operators we track. Geographically, Nang Kuang Pharmaceutical Co., Ltd. is reported in Taiwan, a country with 12 ransomware disclosures in our corpus.

If your organisation is affected

A listing by Incransom means Nang Kuang Pharmaceutical Co., Ltd. appeared on a ransomware extortion site and data attributed to it has been published. If this is your organisation, or a supplier you depend on, the priority is to confirm the intrusion and contain it before the window to act closes.

  • Engage your incident-response team and preserve forensic evidence before remediating — do not wipe affected systems first.
  • Force a password reset and revoke active sessions for exposed accounts; rotate any credentials, API keys or certificates that may have been in the stolen data.
  • Assess regulatory notification duties (GDPR, NIS2, sector regulators) — many carry a 72-hour reporting clock from awareness.
  • Monitor for the data appearing on Incransom's leak site and across paste and breach channels, and brief downstream partners who may be exposed through you.

How we know this. Darkfield monitors public ransomware leak sites continuously, archiving every new disclosure and the data later released against the victim. Each entry on this page is sourced from the operator's own publication and cross-checked against complementary OSINT feeds (RansomLook, ransomware.live, RansomWatch). We do not collect or host stolen data — only the metadata, timestamps and screenshots needed to make the public disclosure searchable and accountable. Records here are corrected when the original post is edited, retracted, or merged with another disclosure.

Nang Kuang Pharmaceutical Co., Ltd. data breach — Incransom ransomware leak (2026) · Darkfield